A Multi-Center, Phase 3, Double-Blind, Randomized, and Controlled Trial of KD019 vs Erlotinib in Subjects With Stage IIIB/IV Non-Small Cell Lung Cancer Who Have Progressed After First- or Second-Line Chemotherapy
Disease/Condition: Non Small Cell Lung Cancer
Principal Investigator: Daniel Morgensztern |
A Phase 1, Open-Label, Multicentre Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-tumor Activity of Ascending Doses of AZD4547 in Patients with Advanced Solid Tumor Malignancies
Disease/Condition: Advanced Solid Cancers
Principal Investigator: Howard S Hochster |
A Phase 1/2 Study of the Oral ALK/EGFR Inhibitor AP26113
Disease/Condition: Advanced Malignancies | Anaplastic Large Cell Lymphoma | Carcinoma, Non-Small-Cell Lung | Diffuse Large Cell Lymphoma | Inflammatory Myofibroblastic Tumors
Principal Investigator: Scott Nicholas Gettinger |
A Phase I/IIa, First Time in human, open-label dose-escalation study of GSK2636771 in subjects with advanced solid tumors with PTEN deficiency
Disease/Condition: Breast Cancer (ER, PR, and HER2 negative) | Colorectal Cancer | Endometrial Cancer | Gastric Adenocarcinoma | Glioblastoma Multiforme | Head/ Neck Squamous Cell Carcinoma | Melanoma | Non-Small Cell Lung Cancer (NSCLC) | Ovarian Cancer | Prostate Cancer
Principal Investigator: Roy Herbst |
A Randomized, Phase III Study Comparing Carboplatin/Paclitaxel or Carboplatin/Paclitaxel/Bevacizumab with or without Concurrent Cetuximab in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC)
Disease/Condition: Non Small Cell Lung Cancer
Principal Investigator: Roy Herbst |
BATTLE-2 Program: A Biomarker-Integrated Targeted Therapy Study in Previously Treated Patients With Advanced Non-Small Cell Lung Cancer
Disease/Condition: Non Small Cell Lung Cancer
Principal Investigator: Roy Herbst |
Chemotherapy With or Without Bevacizumab in Treating Patients With Stage IB, Stage II, or Stage IIIA Non-Small Lung Cancer That Was Removed By Surgery
Disease/Condition: Stage IB Non-small Cell Lung Cancer | Stage IIA Non-small Cell Lung Cancer | Stage IIB Non-small Cell Lung Cancer | Stage IIIA Non-small Cell Lung Cancer
Principal Investigator: Scott Nicholas Gettinger |
